Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study
Victoria P. Werth(Philadelphia VA Medical Center), Shalabh Singhal(Integrated BioTherapeutics (United States)), Thomas Wegman(Bristol-Myers Squibb (United States)), Brian J. Sharkey(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Eric F. Morand(Novartis (Switzerland)), Joan T. Merrill(Oklahoma Medical Research Foundation), Coburn Hobar(Bristol-Myers Squibb (United States)), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Marilyn C. Pike(Bethesda Hospital), Ian M. Catlett(Bristol-Myers Squibb (United States)), Vaishali Shah(Bristol-Myers Squibb (Germany)), Ronald van Vollenhoven(Amsterdam University Medical Centers)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k